vs

Side-by-side financial comparison of SOCKET MOBILE, INC. (SCKT) and TScan Therapeutics, Inc. (TCRX). Click either name above to swap in a different company.

SOCKET MOBILE, INC. is the larger business by last-quarter revenue ($4.0M vs $2.6M, roughly 1.5× TScan Therapeutics, Inc.). SOCKET MOBILE, INC. runs the higher net margin — -287.5% vs -895.1%, a 607.6% gap on every dollar of revenue. On growth, TScan Therapeutics, Inc. posted the faster year-over-year revenue change (286.0% vs -17.9%). SOCKET MOBILE, INC. produced more free cash flow last quarter ($189.3K vs $-32.2M). Over the past eight quarters, TScan Therapeutics, Inc.'s revenue compounded faster (-9.7% CAGR vs -10.8%).

Socket Mobile, Inc. designs, manufactures and sells portable data capture and payment acceptance solutions, including handheld barcode scanners, RFID readers and contactless payment terminals. Its core customer segments cover retail, healthcare, field services and logistics, with products compatible with major mobile operating systems and widely deployed across North America, Europe and Asia Pacific.

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.

SCKT vs TCRX — Head-to-Head

Bigger by revenue
SCKT
SCKT
1.5× larger
SCKT
$4.0M
$2.6M
TCRX
Growing faster (revenue YoY)
TCRX
TCRX
+304.0% gap
TCRX
286.0%
-17.9%
SCKT
Higher net margin
SCKT
SCKT
607.6% more per $
SCKT
-287.5%
-895.1%
TCRX
More free cash flow
SCKT
SCKT
$32.4M more FCF
SCKT
$189.3K
$-32.2M
TCRX
Faster 2-yr revenue CAGR
TCRX
TCRX
Annualised
TCRX
-9.7%
-10.8%
SCKT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SCKT
SCKT
TCRX
TCRX
Revenue
$4.0M
$2.6M
Net Profit
$-11.4M
$-23.0M
Gross Margin
50.2%
Operating Margin
-14.9%
-929.4%
Net Margin
-287.5%
-895.1%
Revenue YoY
-17.9%
286.0%
Net Profit YoY
-29977.8%
35.8%
EPS (diluted)
$-1.43
$-0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SCKT
SCKT
TCRX
TCRX
Q4 25
$4.0M
$2.6M
Q3 25
$3.1M
$2.5M
Q2 25
$4.0M
$3.1M
Q1 25
$4.0M
$2.2M
Q4 24
$4.8M
Q3 24
$3.9M
$1.0M
Q2 24
$5.1M
Q1 24
$5.0M
Net Profit
SCKT
SCKT
TCRX
TCRX
Q4 25
$-11.4M
$-23.0M
Q3 25
$-1.2M
$-35.7M
Q2 25
$-792.1K
$-37.0M
Q1 25
$-994.1K
$-34.1M
Q4 24
$38.1K
Q3 24
$-1.1M
$-29.9M
Q2 24
$-607.6K
Q1 24
$-557.4K
Gross Margin
SCKT
SCKT
TCRX
TCRX
Q4 25
50.2%
Q3 25
47.7%
Q2 25
49.9%
Q1 25
50.4%
Q4 24
51.0%
Q3 24
49.0%
Q2 24
50.9%
Q1 24
50.3%
Operating Margin
SCKT
SCKT
TCRX
TCRX
Q4 25
-14.9%
-929.4%
Q3 25
-34.1%
-1475.6%
Q2 25
-16.8%
-1256.6%
Q1 25
-22.5%
-1669.7%
Q4 24
-8.5%
Q3 24
-26.6%
-3109.8%
Q2 24
-10.5%
Q1 24
-9.7%
Net Margin
SCKT
SCKT
TCRX
TCRX
Q4 25
-287.5%
-895.1%
Q3 25
-38.6%
-1422.1%
Q2 25
-19.6%
-1201.3%
Q1 25
-25.1%
-1571.9%
Q4 24
0.8%
Q3 24
-28.8%
-2849.1%
Q2 24
-12.0%
Q1 24
-11.2%
EPS (diluted)
SCKT
SCKT
TCRX
TCRX
Q4 25
$-1.43
$-0.18
Q3 25
$-0.15
$-0.28
Q2 25
$-0.10
$-0.28
Q1 25
$-0.13
$-0.26
Q4 24
$0.00
Q3 24
$-0.15
$-0.25
Q2 24
$-0.08
Q1 24
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SCKT
SCKT
TCRX
TCRX
Cash + ST InvestmentsLiquidity on hand
$2.0M
$152.4M
Total DebtLower is stronger
$32.5M
Stockholders' EquityBook value
$4.3M
$123.1M
Total Assets
$14.4M
$228.8M
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SCKT
SCKT
TCRX
TCRX
Q4 25
$2.0M
$152.4M
Q3 25
$2.0M
$184.5M
Q2 25
$2.6M
$218.0M
Q1 25
$1.7M
$251.7M
Q4 24
$2.5M
Q3 24
$2.9M
$271.1M
Q2 24
$2.1M
Q1 24
$2.8M
Total Debt
SCKT
SCKT
TCRX
TCRX
Q4 25
$32.5M
Q3 25
$32.4M
Q2 25
$32.3M
Q1 25
$32.2M
Q4 24
Q3 24
$30.6M
Q2 24
Q1 24
Stockholders' Equity
SCKT
SCKT
TCRX
TCRX
Q4 25
$4.3M
$123.1M
Q3 25
$15.7M
$144.0M
Q2 25
$16.7M
$176.7M
Q1 25
$17.2M
$210.2M
Q4 24
$18.2M
Q3 24
$18.0M
$229.1M
Q2 24
$18.8M
Q1 24
$19.2M
Total Assets
SCKT
SCKT
TCRX
TCRX
Q4 25
$14.4M
$228.8M
Q3 25
$25.6M
$262.2M
Q2 25
$27.0M
$298.6M
Q1 25
$27.2M
$332.7M
Q4 24
$27.3M
Q3 24
$27.7M
$348.0M
Q2 24
$28.0M
Q1 24
$28.7M
Debt / Equity
SCKT
SCKT
TCRX
TCRX
Q4 25
0.26×
Q3 25
0.23×
Q2 25
0.18×
Q1 25
0.15×
Q4 24
Q3 24
0.13×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SCKT
SCKT
TCRX
TCRX
Operating Cash FlowLast quarter
$350.4K
$-32.0M
Free Cash FlowOCF − Capex
$189.3K
$-32.2M
FCF MarginFCF / Revenue
4.8%
-1253.3%
Capex IntensityCapex / Revenue
4.1%
6.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-1.8M
$-139.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SCKT
SCKT
TCRX
TCRX
Q4 25
$350.4K
$-32.0M
Q3 25
$-402.8K
$-32.5M
Q2 25
$-464.4K
$-33.3M
Q1 25
$-733.0K
$-37.6M
Q4 24
$-87.0K
Q3 24
$204.0K
$-27.9M
Q2 24
$-543.5K
Q1 24
$-94.9K
Free Cash Flow
SCKT
SCKT
TCRX
TCRX
Q4 25
$189.3K
$-32.2M
Q3 25
$-589.6K
$-33.9M
Q2 25
$-601.4K
$-34.5M
Q1 25
$-785.3K
$-39.1M
Q4 24
$-310.9K
Q3 24
$-192.6K
$-29.3M
Q2 24
$-654.9K
Q1 24
$-151.3K
FCF Margin
SCKT
SCKT
TCRX
TCRX
Q4 25
4.8%
-1253.3%
Q3 25
-19.0%
-1349.6%
Q2 25
-14.9%
-1123.1%
Q1 25
-19.8%
-1801.8%
Q4 24
-6.4%
Q3 24
-5.0%
-2792.0%
Q2 24
-12.9%
Q1 24
-3.0%
Capex Intensity
SCKT
SCKT
TCRX
TCRX
Q4 25
4.1%
6.7%
Q3 25
6.0%
56.8%
Q2 25
3.4%
41.6%
Q1 25
1.3%
70.6%
Q4 24
4.6%
Q3 24
10.2%
130.6%
Q2 24
2.2%
Q1 24
1.1%
Cash Conversion
SCKT
SCKT
TCRX
TCRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-2.28×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons